tousled1
12-16-2007, 12:50 PM
Lapatinib (Tykerb) and capecitabine (Xeloda) were paired in an extension of a Phase 2 clinical trial in which lapatinib given alone shrank brain metastases significantly in six percent of 241 patients
To read full article: http://www.sciencedaily.com/releases/2007/12/071216104315.htm
To read full article: http://www.sciencedaily.com/releases/2007/12/071216104315.htm